EyePoint Pharmaceuticals, Inc. (EYPT) News
Filter EYPT News Items
EYPT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EYPT News Highlights
- For EYPT, its 30 day story count is now at 10.
- Over the past 27 days, the trend for EYPT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about EYPT are AMP, LI and LINK.
Latest EYPT News From Around the Web
Below are the latest news stories about EYEPOINT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate EYPT as an investment opportunity.
Does EyePoint Pharmaceuticals (EYPT) Have the Potential to Rally 336.07% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 336.1% in EyePoint Pharmaceuticals (EYPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregat |
Need To Know: Analysts Are Much More Bullish On EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) RevenuesShareholders in EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) may be thrilled to learn that the analysts have just... |
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2023 Earnings Call TranscriptEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2023 Earnings Call Transcript November 1, 2023 EyePoint Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.33, expectations were $-0.62. Operator: Good morning. My name is Leeway and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Third Quarter […] |
EyePoint Pharmaceuticals Inc (EYPT) Reports Q3 2023 Financial ResultsNet Revenue Increases to $15.2 Million, Up from $10.0 Million in Q3 2022 |
EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments– Positive masked safety data update for EYP-1901 in ongoing PAVIA and DAVIO 2 Phase 2 clinical trials as of October 1, 2023 with no drug related ocular or systemic SAEs reported – – Leadership strengthened with the appointment of Stuart Duty to the Board of Directors and the promotion of George Elston to Executive Vice President – – Topline data for Phase 2 DAVIO 2 trial anticipated in December 2023 and Phase 2 PAVIA trial in 2Q 2024 – – Management to host a conference call and webcast today at |
EyePoint Pharmaceuticals Q3 2023 Earnings PreviewMore on EyePoint Pharmaceuticals |
EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023- KOLs to provide insight and discussion of EYP-1901 in wet AMD and topline data considerations for the DAVIO 2 clinical trialWATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced it will host a virtual key opinion leader (KOL) event on Thursday, November 9, 2023 from 8:00 to 9:00 am ET. This event will focus on th |
EyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference 2023WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced that the Company will present at upcoming medical meetings and an investor conference. Presentation details are as follows: Eyecelerator 2023 Title: The Year in ReviewForum: Panel DiscussionDate: Thursday, November 2, 2023Time: 8:10 a.m. PT / 11:1 |
EyePoint Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 1, 2023WATERTOWN, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 1, 2023 to report its third quarter 2023 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio con |